WallStreetZenWallStreetZen

NASDAQ: TVTX
Travere Therapeutics Inc Earnings & Revenue

TVTX past revenue growth

How has TVTX's revenue growth performed historically?
Company
28.61%
Industry
80.9%
Market
15.78%
TVTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
TVTX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
TVTX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

TVTX earnings and revenue history

Current Revenue
$183.2M
Current Earnings
-$161.1M
Current Profit Margin
-87.9%

TVTX Return on Equity

Current Company
-96%
Current Industry
16.6%
Current Market
28.2%
TVTX's Return on Equity (-96%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when TVTX announces earnings.

TVTX Return on Assets

Current Company
-21.3%
Current Industry
3.1%
TVTX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

TVTX Return on Capital Employed

Current Company
-30.48%
Current Industry
-43.5%
TVTX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

TVTX vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
TVTX$183.23M-$110.58M-$161.13M+2.07%N/A
APLT-$477.00k-$193.21M-$193.56MN/AN/A
PEPG$0.00-$78.88M-$80.33MN/AN/A
EDIT$69.41M-$179.30M-$166.13M+18.20%N/A
ABSI$5.35M-$94.31M-$109.19M+24.34%N/A

Travere Therapeutics Earnings & Revenue FAQ

What were TVTX's earnings last quarter?

On Invalid Date, Travere Therapeutics (NASDAQ: TVTX) reported Q1 2024 earnings per share (EPS) of -$1.76, up 38.58% year over year. Total Travere Therapeutics earnings for the quarter were -$136.06 million. In the same quarter last year, Travere Therapeutics's earnings per share (EPS) was -$1.27.

If you're new to stock investing, here's how to buy Travere Therapeutics stock.

What was TVTX's earnings growth in the past year?

As of Q2 2024, Travere Therapeutics's earnings has grown year over year. Travere Therapeutics's earnings in the past year totalled -$161.13 million.

What was TVTX's revenue last quarter?

On Invalid Date, Travere Therapeutics (NASDAQ: TVTX) reported Q1 2024 revenue of $41.37 million up 33.95% year over year. In the same quarter last year, Travere Therapeutics's revenue was $30.89 million.

What was TVTX's revenue growth in the past year?

As of Q2 2024, Travere Therapeutics's revenue has grown 28.61% year over year. This is 52.3 percentage points lower than the US Biotechnology industry revenue growth rate of 80.9%. Travere Therapeutics's revenue in the past year totalled $183.23 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.